SHANGHAI, Nov. 12, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 10, 2010.
At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class C directors Dr. Ge Li, Cuong Viet Do and Stewart Hen, each to serve a three-year term.
In addition, the WuXi shareholders approved a proposal to amend the WuXi PharmaTech (Cayman) Inc. 2007 Employee Share Incentive Plan to increase the number of ordinary shares authorized to be issued pursuant to the Plan, as well as to limit the total number of ordinary shares that may be delivered pursuant to options qualified as incentive stock options granted under the Plan.
About WuXi PharmaTechWuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.For more information, please contact:WuXi PharmaTech (Cayman) Inc.Ronald Aldridge (for investors)Director of Investor RelationsTel: +1-201-585-2048Email: firstname.lastname@example.orgStephanie Liu (for the media)WuXi PharmaTech (Cayman) Inc.Tel: +86-21-5046-4362Email: email@example.com
|SOURCE WuXi PharmaTech (Cayman) Inc|
Copyright©2010 PR Newswire.
All rights reserved